Stem cell therapy for dilated cardiomyopathy

Abstract

We are uncertain whether SCT in people with DCM reduces the risk of all-cause mortality and procedural complications, improves HRQoL, and performance status (exercise capacity). SCT may improve functional class (NYHA), compared to usual care (no cells).Similarly, when compared to G-CSF, we are also uncertain whether SCT in people with DCM reduces the risk of all-cause mortality although some studies within this comparison observed a favourable e ect that should be interpreted with caution. SCT may not improve HRQoL but may improve to some extent performance status (exercise capacity). Very low-quality evidence reflects uncertainty regarding procedural complications. These suggested beneficial e ects of SCT, although uncertain due to the very low certainty of the evidence, are accompanied by favourable e ects on some physiological measures of cardiac function.Presently, the most e ective mode of administration of SCT and the population that could benefit the most is unclear. Therefore, it seems reasonable that use of SCT in people with DCM is limited to clinical research settings. Results of ongoing studies are likely to modify these conclusions.

The role of the angiography-derived index of microcirculatory resistance in the prognosis of patients with dilated cardiomyopathy

“…We maintain a positive outlook on the treatment of CMD in patients with DCM. In addition to the drugs and devices commonly used in clinical practice, it has been reported that transplantation of CD34 (+) stem cells can promote the formation of new blood vessels in ischemic tissue by immediately incorporating cells brought into the creating vascular system or using producing and secreting angiogenic cytokines (38,39). Inhibitors of cyclic nucleotide phosphodiesterase PDE3 with vasodilatory actions may also be considered an adjunct therapy for DCM (40).…”